Sarepta says its experimental Duchenne drug more effective than older medicine

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-01-30 06:00 GMT | Update On 2024-03-22 12:10 GMT

New Delhi: Sarepta Therapeutics' experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD) than its older drug Exondys 51 when tested in a mid-stage trial, the company said on Monday.

DMD is a genetic muscle wasting disorder that affects an estimated one-in-3,500 male births worldwide, and the majority of the patients lack the protein dystrophin which keeps muscles intact.

The drug SRP-5051 and Exondys 51 both belong to a class of "exon-skipping" therapies, which work by skipping specific parts of genes, called exons, to allow the body to make shorter forms of the dystrophin protein. Both drugs are given to specific patients who can be treated by skipping exon 51.

Also Read:FDA rejects BioMarin's muscle wasting drug; Sarepta drug in focus

Sarepta said the new drug, when given every four weeks, showed an over 12-fold increase in dystrophin expression and a nearly 25-fold increase in exon skipping after 28 weeks compared to weekly dosing of Exondys 51.

Exondys 51, the company's first DMD treatment that treats the disorder by skipping exon 51, was approved in 2016 and generated revenue of $409.6 million in the first nine months of 2023 and was Sarepta's biggest product.

The company's portfolio also consist of two more drugs for DMD, Vyondys 53 and Amondys 45, which are used to treat patients by skipping exon 53 and 45, respectively.

The company has also secured the U.S. Food and Drug Administration's accelerated approval in June last year for a gene-therapy to treat four to five-year olds with DMD. It is currently awaiting full approval for the therapy.

Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/sarepta-says-its-experimental-duchenne-drug-more-effective-than-older-medicine-2024-01-29/

Also Read:FDA gives nod to novel steroid for treatment of Duchenne muscular dystrophy

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Kajal Rajput

Kajal Rajput joined Medical Dialogues as an Correspondent for the Latest Health News Section in 2019. She holds a Bachelor's degree in Arts from University of Delhi. She manly covers all the updates in health news, hospitals, doctors news, government policies and Health Ministry. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sarepta says its experimental Duchenne drug more effective than older medicine

Similar News

NPPA fixes Special Ceiling Price for Gufic's Meropenem Dual Chamber Bags

Sun Pharma Fails to Secure CDSCO Nod for BE, Phase III Waiver on Sitagliptin, Glimepiride, Metformin FDC

USFDA approves expanded indication for Takeda Vonvendi for adults, children with Von Willebrand Disease

Roche receives EU CE mark for Contivue for neovascular age-related macular degeneration

Drug Safety Alert: IPC Flags Adverse Reactions linked to Tranexamic acid and Metoclopramide

Virchow Biotech gets CDSCO panel nod to study Semaglutide for chronic weight management

SC Questions Effectiveness of UCPMP, Seeks Govt Clarification on Pharma Freebies

Dr Reddy's Labs API Mirfield facility gets 7 USFDA observations